Tables and Figures
48
Figure 9. DATA Framework for Second-line Therapy of RAIR DTC
DATA framework for treatment of patients with progression on (or intolerance to) first-line therapy
for RAIR metastatic DTC.
a
Biopsy of progressive disease when acquired resistance emerges is advised to evaluate for potentially
actionable resistant mechanisms.
b
If targeted therapy or clinical trial is not available, cabozantinib or another MKI may be considered
in patients treated with lenvatinib first-line.
Biopsy at progression with
comprehensive somatic
genomic testing
a
RET and NTRK
fusion-positive
on gene-specific
therapy
Actionable
acquired
resistance
mutation
RET, NTRK, BRAF
wildtype
No actionable
mutation
BRAF V600E
mutation-
positive
Diagnosis and
Assessment for
Progression on
Therapy
RAIR DTC
with progression on
1st-line therapy with
good performance
status
No actionable
mutation
